Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Return on Sales (2020 - 2025)

Historic Return on Sales for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to 33.51%.

  • Kymera Therapeutics' Return on Sales fell 142100.0% to 33.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 1397.46%, marking a year-over-year increase of 13997500.0%. This contributed to the annual value of 84.48% for FY2024, which is 823700.0% down from last year.
  • Per Kymera Therapeutics' latest filing, its Return on Sales stood at 33.51% for Q3 2025, which was down 142100.0% from 7.38% recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Return on Sales ranged from a high of 2.21% in Q4 2024 and a low of 33.51% during Q3 2025
  • For the 5-year period, Kymera Therapeutics' Return on Sales averaged around 5.74%, with its median value being 3.37% (2025).
  • As far as peak fluctuations go, Kymera Therapeutics' Return on Sales soared by 29900bps in 2021, and later tumbled by -142100bps in 2025.
  • Over the past 5 years, Kymera Therapeutics' Return on Sales (Quarter) stood at 2.23% in 2021, then fell by -8bps to 2.4% in 2022, then soared by 83bps to 0.4% in 2023, then surged by 646bps to 2.21% in 2024, then tumbled by -1617bps to 33.51% in 2025.
  • Its Return on Sales was 33.51% in Q3 2025, compared to 7.38% in Q2 2025 and 3.37% in Q1 2025.